Market capitalization | $542.68m |
Enterprise Value | $285.40m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.21 |
P/S ratio (TTM) P/S ratio | 4.20 |
P/B ratio (TTM) P/B ratio | 1.61 |
Revenue growth (TTM) Revenue growth | 15.52% |
Revenue (TTM) Revenue | $129.33m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
6 Analysts have issued a Quanterix Corporation forecast:
6 Analysts have issued a Quanterix Corporation forecast:
Dec '23 | |
Current assets | 378 378 |
Fixed assets | 52 52 |
Total Assets | 431 431 |
Dec '23 | |
Equity | 347 347 |
Debt capital | 84 84 |
Total Capital | 431 431 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its Single Molecule Array (Simoa) technology platform uses single molecule measurements to access previously undetectable proteins. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Billerica, MA.
Head office | United States |
CEO | Masoud Toloue |
Employees | 441 |
Founded | 2007 |
Website | www.quanterix.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.